Effects of entinostat onresistance to cetuximab and EGFR TKIs in non-small cell lung cancer

被引：0
|
作者：
Witta, Samir E.
Chan, Dan
Girard, Luc
Zheng, Di
Franekova, Veronica
Peyton, Michael
Zhang, Zhi-Yong
Kline, Zoe
Minna, John D.
Bunn, Paul A.
Hirsch, Fred R.
机构：
[1] Mt Blue Canc Care Ctr, Golden, CO USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[4] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18077
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs
    Tone, Mari
    Iwahori, Kota
    Shiroyama, Takayuki
    Futami, Shinji
    Naito, Yujiro
    Fukushima, Kiyoharu
    Miyake, Kotaro
    Koyama, Shohei
    Hirata, Haruhiko
    Nagatomo, Izumi
    Wada, Hisashi
    Takeda, Yoshito
    Kumanogoh, Atsushi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [32] Outcomes of EGFR-TKIs for patients with non-small cell lung cancer harboring EGFR mutations with poor performance status
    Hashimoto, K.
    Okuma, Y.
    Hakozaki, T.
    Watanabe, K.
    Hosomi, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Differential effects of GA201 and cetuximab on EGFR expression and endosomal recycling in non-small cell lung cancer cell lines
    Kol, Arjan
    de Jong, Steven
    Pool, Martin
    de Vries, Elisabeth G. E.
    Gerdes, Christian A.
    van Scheltinga, Anton G. T. Terwisscha
    CANCER RESEARCH, 2014, 74 (19)
  • [34] Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer
    Kubo, Naoki
    Harada, Taishi
    Shiraishi, Yoshimasa
    Nosaki, Kaname
    Nakagaki, Noriaki
    Takeshita, Masafumi
    Ouchi, Hiroshi
    Iwama, Eiji
    Tanaka, Kentaro
    Okamoto, Isamu
    Sasaki, Hiroyuki
    Nakanishi, Yoichi
    ANTICANCER RESEARCH, 2019, 39 (02) : 671 - 677
  • [35] Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer
    Takemura, Yoshizumi
    Chihara, Yusuke
    Morimoto, Yoshie
    Tanimura, Keiko
    Imabayashi, Tatsuya
    Seko, Yurie
    Kaneko, Yoshiko
    Date, Koji
    Ueda, Mikio
    Arimoto, Taichiro
    Iwasaki, Yoshinobu
    Takayama, Koichi
    ANTICANCER RESEARCH, 2018, 38 (04) : 2385 - 2390
  • [36] Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer
    Shi, Xiaoshun
    Dong, Xiaoying
    Zhai, Jianxue
    Liu, Xiguang
    Lu, Di
    Ni, Zhen
    Wu, Hua
    Cai, Kaican
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Effects of metformin on a non-small cell lung cancer cell line with an EGFR mutation
    Kitazono, Satoru
    Takiguchi, Yuichi
    Ashinuma, Hironori
    Kitazono, Miyako
    Kitamura, Atsushi
    Tada, Yuji
    Kurosu, Katushi
    Sakaida, Emiko
    Sekine, Ikuo
    Tatsumi, Koichiro
    CANCER RESEARCH, 2012, 72
  • [38] A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer
    Cheng, Hua
    Li, Xiao-Jian
    Wang, Xiao-Jin
    Chen, Zuo-Wen
    Wang, Rui-Qi
    Zhong, Hong-Cheng
    Wu, Tian-Chi
    Cao, Qing-Dong
    LUNG CANCER, 2019, 137 : 7 - 13
  • [39] Chemotherapy plus EGFR-TKIs versus EGFR-TKIs Alone in Non-small Cell Lung Cancer with EGFR-Activating Mutations: A Meta-analysis
    Han, G.
    Peng, M.
    Weng, Y.
    Zou, J.
    Song, Q.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E458 - E458
  • [40] Cancer stem cell-like population from non-small cell lung cancer is preferentially suppressed by EGFR-TKIs.
    Yang, Fan
    You, Jiacong
    Li, Yang
    Liao, Jiayu
    Zhou, Qinghua
    CANCER RESEARCH, 2013, 73 (08)
12345